Table 6 Ongoing phase 4 trials
From: Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Agent | Mechanism of action | Target type and therapeutic purpose | ClinicalTrials.gov identifier | Status |
|---|---|---|---|---|
Escitalopram Oxalate | Selective-serotonin reuptake inhibitor | Neuropsychiatric symptoms (depression) | NCT05004987 | Recruiting |
Sodium Oligomannate Capsule (GV-971) | Neuroinflammation inhibitor, Aβ fibril formation inhibitor | Anti-neuroinflammation, amyloid-related | NCT05181475 | ACTIVE, NOT RECRUITING |
NCT05430867 | Not yet recruiting | |||
Spironolactone | Aldosterone mineralocorticoid receptor antagonist | Anti-neuroinflammation | NCT04522739 | Recruiting |